A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2009 |
| End Date: | June 2013 |
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
This open-label single-arm study will evaluate the effect of RO5185426 [RG7204; PLEXXIKON:
PLX4032] on the pharmacokinetics of five CYP450 substrates (caffeine, warfarin + vitamin K,
omeprazole, dextromethorphan, midazolam) administered as a drug cocktail to patients with
metastatic melanoma. The study will also evaluate efficacy and safety of RO5185426. On day
1, patients will receive the drug cocktail. On days 6 to 19, patients will receive RO5185426
twice daily. On day 20, patients will receive RO5185426 and the drug cocktail and on days 21
to 25, patients will receive RO5185426. Assessments will be made at regular intervals during
the dosing periods and at follow-up. Patients may continue on study treatment (RO5185426)
until the development of progressive disease or unacceptable toxicity. Target sample size
<50.
PLX4032] on the pharmacokinetics of five CYP450 substrates (caffeine, warfarin + vitamin K,
omeprazole, dextromethorphan, midazolam) administered as a drug cocktail to patients with
metastatic melanoma. The study will also evaluate efficacy and safety of RO5185426. On day
1, patients will receive the drug cocktail. On days 6 to 19, patients will receive RO5185426
twice daily. On day 20, patients will receive RO5185426 and the drug cocktail and on days 21
to 25, patients will receive RO5185426. Assessments will be made at regular intervals during
the dosing periods and at follow-up. Patients may continue on study treatment (RO5185426)
until the development of progressive disease or unacceptable toxicity. Target sample size
<50.
Inclusion Criteria:
- Adult patient >/= 18 years of age
- Malignant melanoma (Stage IV, AJCC)
- Patients who are treatment-naive or have received prior systemic treatments for
metastatic melanoma. Time elapsed between previous treatment for metastatic disease
and first administration of study drug must be at least 28 days
- Positive tested for BRAF mutation
- Patients must not be poor metabolizers of CYP450 enzymes 2C9, 2C19, or 2D6 as
determined by genotyping
- Measurable disease by RECIST criteria
- Negative pregnancy test; for fertile men and women, effective contraception during
treatment and for 6 months after completion
Exclusion Criteria:
- Active CNS lesions on CT/MRI within 28 days prior to enrollment
- History of known spinal cord compression, or carcinomatous meningitis
- Severe cardiovascular disease within 6 months prior to study
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials